Cargando…
SGLT2-Inhibitoren: Was gibt es Neues?
Sodium-glucose transport protein 2 inhibitors (SGLT2i, gliflozins) were originally developed for the treatment of type 2 diabetes; however, in mandatory approval studies, they demonstrated unexpected positive effects on cardiovascular endpoints and renal function. Several phase III studies published...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Medizin
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245922/ https://www.ncbi.nlm.nih.gov/pubmed/34226841 http://dx.doi.org/10.1007/s11560-021-00511-4 |